Marksans Pharma Q2FY27 Revenue Surges 30.5% to ₹940 Cr, EBITDA Up 48.3%
Marksans Pharma reported record Q2FY27 results with revenue at ₹940 crore (+30.5% YoY) and EBITDA at ₹214 crore (+48.3% YoY). H1FY27 revenue grew 32.9% to ₹1,781 crore, with EBITDA at ₹427 crore (+74.7% YoY). PAT for H1FY27 nearly doubled to ₹303 crore. The company ended with ₹1,124 crore cash.
The announcement details record financial results, significant growth across multiple metrics and geographies, and a strong cash position. This level of positive performance is likely to have a substantial impact on investor sentiment and the company's market valuation.
The company reported record-breaking financial performance with significant year-on-year growth in revenue, EBITDA, and PAT across both Q2FY27 and H1FY27. Key geographical regions showed strong performance, and cash generation remained robust, indicating a positive financial outlook.
Marksans Pharma Limited announced its financial results for the second quarter and first half of fiscal year 2027 (Q2FY27 and H1FY27), reporting a landmark performance with its strongest-ever quarter.
For Q2FY27, the company's revenue reached ₹940 crore, marking a significant year-on-year increase of 30.5%. Adjusted for the acquisition impact of QliniQ, the organic revenue growth was a healthy 25%. EBITDA for the quarter grew by 48.3% to a record ₹214 crore, with EBITDA margins expanding by 274 basis points to 22.8%. Profit After Tax (PAT) rose by 44.8% to ₹144 crore.
The first half of FY27 (H1FY27) also demonstrated robust growth. Revenue increased by 32.9% year-on-year to ₹1,781 crore. EBITDA surged by 74.7% to ₹427 crore, with margins improving by 574 basis points to 24.0%. PAT nearly doubled to ₹303 crore, already exceeding 70% of the full-year FY26 profit.
Growth was broad-based across geographies. The UK & Europe region saw a remarkable increase of 64.9% to ₹405 crore in Q2FY27, with the base business growing 48.6% organically and QliniQ contributing approximately ₹84 crore in H1FY27. Australia & New Zealand grew by 64.0%, and the US & North America region achieved its highest-ever quarterly revenue at ₹421 crore.
Cash generation remained strong, with H1 operating cash flow reaching ₹322 crore (4.3 times the previous year). The company ended the period with cash balances of ₹1,124 crore. Trailing twelve-month ROCE improved to 24.7%.
Mark Saldanha, Founder, Chairman & Managing Director, expressed confidence in the company's trajectory, highlighting the expanding global footprint, robust product pipeline, and strong net-cash position. The company remains focused on sustaining profitable organic growth while selectively pursuing strategic acquisitions.
What to do with a filing like this
Marksans Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Marksans Pharma Limited. Read the original for the full detail.